Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 July 2020 | Story Nitha Ramnath | Photo istock

Date: 28 July 2020
Time: 14:00 – 15:30

Gender inequalities domestic violence and gender-based violence (GBV) are global concerns, and have been exacerbated by the impact of Covid-19 as women take on more child and care work responsibilities.  Jobs lost in service sectors often affect women most, large numbers of frontline health workers and teachers are women, and lockdowns increase domestic violence. Thus President Cyril Ramaphosa recently said in a televised address that more than 21 women and children have been murdered in South Africa within just a few weeks in what he referred to as “another pandemic raging in our country.” He said this “violence being unleashed on women and children with a brutality that defies comprehension, is no less than a war being waged against the women and children of our country”.

As the World Economic Forum points out, regardless of where one looks, it is women who bear most of the responsibility for holding societies together, be it at home, in health care, at school, or in caring for the elderly. In many countries, women perform these tasks without pay. 

Now, the Covid-19 pandemic is compounding existing gender inequalities, and increasing risks of gender-based violence. Gender inequality, layered along with the effects of the pandemic, lockdowns and the economic downturn, could leave a deep and lasting impact on the lives and opportunities of women and girls.

Given, then, that the COVID-19 crisis affects women and girls in different ways from men and boys, measures to resolve it must take gender into account, and the protection and promotion of the rights of women and girls prioritized. 
To take up these issues of gender inequalities and gender-based violence, two renowned gender research experts will take part in our webinar. The webinar will be chaired by Professor Melanie Walker of the University of the Free State.  The presenters are: Professor Pumla Gqola, Professor of Women and Gender Studies at Nelson Mandela University and author of Rape: A South African Nightmare. Lisa Vetten has worked in the field of violence against women for over two decades as a counsellor, para-legal, trainer and researcher. She is currently an honorary research associate at the Wits Institute for Social and Economic Research (WiSER).

Join us from 14:00 to 15:30 on 28 July. 

RSVP to Sibongile Mlotya at MlotyaS@ufs.ac.za no later than 26 July, upon which you will receive a Business for Skype meeting invite.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept